Company Dynamics Update
On April 15, 2025, Jiangsu Lianhuan Pharmaceutical Co., Ltd. (Lianhuan Pharmaceutical) announced that its Mecobalamin Injection successfully passed the generic drug quality and efficacy consistency evaluation. The approval was granted through a “Drug Supplemental Application Approval Notice” issued by China’s National Medical Products Administration (NMPA).
Product Overview and Clinical Use
Mecobalamin Injection is primarily used to treat:
- Macrocytic anemia caused by vitamin B12 deficiency
- Peripheral neuropathy, including various nerve disorders related to low vitamin B12 levels
By securing consistency evaluation approval, Lianhuan Pharmaceutical ensures that its Mecobalamin Injection is equivalent in quality and clinical efficacy to the original reference drug, supporting broader clinical acceptance and healthcare procurement opportunities.
Regulatory Significance
Passing the generic drug consistency evaluation marks a major milestone for pharmaceutical companies in China. It demonstrates compliance with high standards for:
- Pharmaceutical quality
- Therapeutic equivalence
- Safety and efficacy
The evaluation strengthens Lianhuan Pharmaceutical’s market competitiveness and enhances the accessibility of cost-effective, high-quality treatments in China’s healthcare system.
Company Background
Established in Jiangsu Province, Lianhuan Pharmaceutical is a leading pharmaceutical enterprise engaged in the research, development, production, and sale of a broad range of pharmaceutical products. The company focuses on therapeutic areas such as neurology, hematology, and chronic disease management.
Industry Outlook
With China’s ongoing emphasis on healthcare reform and generic drug quality upgrades, consistency evaluations are critical for pharmaceutical market access and reimbursement listings. Lianhuan Pharmaceutical’s success positions it strongly for future growth in the competitive neurological and hematological treatment segments.
Accelerate Your Business with China Informatics
Partner with China Informatics for:
- Real-time news and regulatory reports from China’s pharmaceutical sector.
- Strategic insights on consistency evaluations and market entry strategies.
- Comprehensive analysis of company dynamics and healthcare market trends in China.
Lead your industry with expert intelligence designed for innovators and decision-makers. Connect with China Informatics today.
